Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Cancer ; 108(3): 443-9, 2004 Jan 20.
Article in English | MEDLINE | ID: mdl-14648712

ABSTRACT

Lymphoproliferative disorders (LPD) occasionally develop in individuals with immune deficiencies such as immunosuppressive conditions and autoimmune diseases (AID). In our study, the clinicopathologic features and virus status were analyzed in 53 cases with LPD developing in rheumatoid arthritis (RA) and other AID. AID in only 4 of 53 patients had been treated with some sort of immunosuppressive therapy, including methotrexate. Median age at the diagnosis of LPD in AID was 60 years old with marked female predominance (M/F = 0.4). The median interval between the onset of AID and LPD development was 45 months, and longer in RA patients than in other AID (p < 0.01). The primary site of lymphoma was nodal in 21 cases and extra-nodal in 24, with clinical Stage I in 17, II in 5, III in 13, and IV in 13. Immunohistochemistry showed that 39 cases were B cell type, 10 were T cell type and 4 were Hodgkin lymphoma (HL). Then majority of B cell cases were diffuse large B cell lymphomas, and 2 were diffuse polymorphic type. EBER-1 in situ hybridization for Epstein-Barr virus (EBV) showed positive signals in tumor cells in 16 of 53 (30.2%) cases. The EBV-positive rate in T cell LPD (70%) was much higher than that in B cell LPD (12.8%) (p < 0.01). All 4 cases of HL were EBV-positive. Immunohistochemistry showed a latency II pattern of EBV infection (LMP-1(+) and EBNA-2(-)). Five-year overall survival rate was 33%. Multivariate analysis showed that only type of AID was an independent factor for survival of patients, i.e., LPD in RA showed the most favorable prognosis. In conclusion, LPD in AID generally shared common features with sporadic LPD except for a much higher EBV-positive rate in T cell LPD.


Subject(s)
Autoimmune Diseases/complications , Epstein-Barr Virus Infections/complications , Lymphoma/complications , Adult , Aged , Aged, 80 and over , Autoimmune Diseases/mortality , Autoimmune Diseases/pathology , Epstein-Barr Virus Infections/mortality , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Nuclear Antigens/metabolism , Female , Herpesvirus 4, Human/physiology , Humans , Japan/epidemiology , Lymphoma/mortality , Lymphoma/pathology , Male , Middle Aged , Prognosis , RNA, Viral/metabolism , Survival Rate , Treatment Outcome , Viral Matrix Proteins/metabolism
2.
Plant Cell Physiol ; 43(11): 1314-22, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12461131

ABSTRACT

Genes responding to Nod factors were picked up by the application of a differential display method for soybean suspension-cultured cells. Forty-five cDNA fragments derived from such genes were detected. Seven fragments (ssc1-ssc7) were successfully cloned. The putative product of genes corresponding to ssc1 was estimated to be a disease-resistance protein relating to the induction of the plant defense response against pathogens, and that corresponding to ssc7 was a sucrose transporter. Amino acid sequences deduced from full-length cDNA corresponding to ssc2 and ssc4 were investigated, and it was shown that these polypeptides were equipped with a leucine zipper motif and with phosphorylation sites that were targeted by tyrosin kinase and cAMP-dependent protein kinase, respectively. In a differential display experiment, the transcriptional levels of three genes corresponding to ssc2, ssc3 and ssc5 were estimated to be up-regulated at 6 h after initiation of the treatment and the remaining four were estimated to be down-regulated. However, transcription of the genes corresponding to all ssc was clearly repressed within 2 h after initiation of the treatment. Five of them were restored to their transcriptional level 6 h after initiation of the treatment, although the others were repressed throughout the experimental period.


Subject(s)
Glycine max/genetics , Lipopolysaccharides/pharmacology , Soybean Proteins/genetics , Transcription, Genetic/genetics , Amino Acid Sequence , Base Sequence , Cells, Cultured , Cloning, Molecular , DNA, Complementary/chemistry , DNA, Complementary/genetics , Gene Expression Regulation, Plant/drug effects , Immunity, Innate/genetics , Membrane Transport Proteins/genetics , Molecular Sequence Data , Plant Proteins/genetics , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Soybean Proteins/drug effects , Soybean Proteins/metabolism , Glycine max/cytology , Glycine max/drug effects , Symbiosis/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...